TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Rectal Indomethacin to Prevent Post ESWL-pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* any patient with chronic pancreatitis and pancreatic stones (\> 5 mm in diameter) undergoing P-ESWL~* at least 18 years old~* provides informed consent~Exclusion Criteria:~* readmitted to the hospital during the enrollment of the study~* contraindications to ESWL~* suspected or established malignancy~* pancreatic ascites~* receiving NSAIDs within 7 days~* contraindication to NSAIDs (including gastrointestinal hemorrhage within 4 weeks or renal dysfunction with serum creatinine \>120 μmol/L)~* presence of coagulopathy or received anticoagulation therapy within 3 days~* acute pancreatitis within 3 days~* known active cardiovascular or cerebrovascular disease~* pregnant or breastfeeding women~* without a rectum (ie, status post-total proctocolectomy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indomethacin (Type: EXPERIMENTAL): Subjects will be randomized to receive a 100-mg indomethacin suppository 30 min before ESWL.
- Glycerin (Type: PLACEBO_COMPARATOR): Subjects will be randomized to receive either a 100-mg identical-appearing placebo (glycerin suppository) 30 min before ESWL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 19+~2. Patients treated with a new generation of Evelorimus-eluting stents (Synergy®)~3. Patients who understand the content of the subject description and voluntarily sign the subject~Exclusion Criteria:~1. Age 86+~2. Hemodynamically unstable patient~3. Severe hypersensitivity reactions to aspirin, clopidogrel, ticagrelor, everolimus, contrast agent~4. Patients at high risk of bleeding, anemia, thrombocytopenia~5. Patients requiring oral anticoagulants~6. Pregnant women or women of childbearing age~7. Life expectancy is less than one year~8. Patients receiving a potent CYP3A4 inhibitor (eg, ketoconazole, clarithromycin, napjodone, ritonavir, atazanavir)~9. Patients with a history of intracranial hemorrhage~10. Patients with moderate to severe hepatic impairment~11. Patients underwent coronary intervention with stenting within 1 year~12. Patients with left-main lesions requiring coronary intervention~13. Patients with chronic stricture lesions requiring treatment~14. Patients with in-stent restenosis in a lesion requiring treatment~15. Patients with bifurcation lesions requiring stenting in lateral branches~16. Patients with lesions requiring more than 3 stents

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- P2Y12 antagonist monotherapy (Type: EXPERIMENTAL): P2Y12 antagonist monotherapy after 3-month DAPT
- Aspirin + P2Y12 antagonist (Type: ACTIVE_COMPARATOR): Aspirin + P2Y12 antagonist after 3-month DAPT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Novel Device for the Management of ADHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented history of primary ADHD diagnosis by certified clinicians~* Age 18-40 y~* Written informed consent~* Able and willing to complete all required ratings and assessments~Exclusion criteria:~* Any current psychiatric / neurological comorbidity (e.g., epilepsy, Autism, depression, TBI, etc), other than ADHD~* ADHD Medications (stimulants, non-stimulants, other)~* Neurofeedback, cognitive training

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): VIZO Glasses- personalized

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed diagnosis of carcinoma~* Stage II-III (T2, T3, N0 or T1-3, N1) carcinoma of head and neck, including: oral cavity, pharynx, larynx, paranasal sinuses, and cervical esophagus~* No N2 or N3~* Measurable disease is not required~PATIENT CHARACTERISTICS:~Age:~* Not specified~Performance status:~* Zubrod 0-3~Life expectancy:~* Anticipated survival is 3-4 years (median)~Hematopoietic:~* WBC count at least 3.5/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Not specified~Renal:~* Not specified~Cardiovascular:~* Not specified~Pulmonary:~* Not specified~Other:~* No infection or severe medical illness~* Not pregnant~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy~Surgery:~* No prior surgery

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Hyper-FHX) (Type: EXPERIMENTAL): Concomitant chemoradiotherapy consisting of hydroxyurea (PO, BID, x 6days), continuous infusion 5-fluorouracil (IV, x 5days), hyperfractionated radiotherapy (150 cGy twice daily for 5 days every 14 days, 5 cycles)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 or Type 2 diabetes mellitus~* 18 years or older~* Meet specific requirements for diabetic retinopathy~* Free of severe or chronically disabling conditions, except diabetes, diabetic retinopathy and diabetic macular edema~* Hemoglobin A1c (HbA1C) ≤13.0%~Exclusion Criteria:~* History of panretinal photocoagulation for diabetic retinopathy, conditions that might affect the progression of diabetic retinopathy, or unstable angina~* Investigators, site personnel directly affiliated with the study and their families~* Presence of eye disorders that may affect the progression of diabetic retinopathy or cause vision loss~* Presence of medical disorder, cancer, or elevated laboratory measurements that could represent a safety risk during the study~* Women who are pregnant, breastfeeding, intend to become pregnant, or who are sexually active without using an acceptable method of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruboxistaurin (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Monotherapy With Noradrenaline and Terlipressin in Patients of Cirrhosis With Septic Shock Admitted to Intensive Care Unit

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient of cirrhosis or ACLF (Acute on Chronic Liver Failure) with septic shock (defined later).~* Age 18-70yrs~* An informed consent from the patient or relative~Exclusion Criteria:~* Pronounced cardiac dysfunction( valvular heart disease, coronary artery disease),~* Acute mesenteric ischemia (confirmed or suspected) or vasospastic diathesis (e.g. Reynaud's syndrome or related diseases).~* Pregnancy~* Previous history of transplantation on immunosuppressant.~* Acute gastrointestinal bleed.(defined later)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Noradrenaline (Type: ACTIVE_COMPARATOR): Noradrenaline: Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)\>65.
- Terlipressin (Type: EXPERIMENTAL): Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)\>65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Human Urinary Kallidinogenase Improve Short Term Motor Functional Outcome of Acute Ischemia Stroke Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~18 years old ≤ age \<80 years old; Within 72 hours of onset; Diagnosed as acute cerebral infarction, and confirmed by magnetic resonance imaging as an acute infarct in the unilateral corticospinal tract; The patient's onset muscle strength grade \<4; No history of cerebral infarction or residual physical activity disorder; No other intracranial lesions; Patients or their legal representatives voluntarily Sign the informed consent form;~Exclusion Criteria:~Intracranial hemorrhagic disease: cerebral hemorrhage, subarachnoid hemorrhage, etc.; Transient ischemic attack; Intravenous thrombolysis and interventional thrombectomy; Serious physical illness affects limb movement before enrollment ; Apply other drugs with nutritional nerves and regeneration during the study period; Unstable vital signs, severe liver and kidney diseases or malignant tumors; Incomprehensible or incapable of obeying the research procedure or being unable to follow up due to mental illness, cognitive or emotional disorders;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Kallikrein+Standard treatment group (Type: EXPERIMENTAL): The Kallikrein+Standard treatment group was given kallikrein through intravenous injection to treatment for 0.15 PNA/day+standard treatment medicine based on the guidelines for the treatment of acute ischemic stroke for 14 ± 5 days.
- Standard treatment group (Type: NO_INTERVENTION): The Standard treatment group was only given standard treatment medicine based on the guidelines for the treatment of acute ischemic stroke for 14 ± 5 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 years of age~* Histologically or cytologically confirmed CRC that is metastatic~* Presence of BRAF V600E in tumor tissue determined by local assay at any time prior to screening~* Evidence of measurable disease as per RECIST, v1.1~* Subject able to receive cetuximab as per approved label with regards to RAS status~* Eastern Cooperative Oncology Group Status (ECOG) 0 or 1~* Adequate renal, hepatic, cardiac and bone marrow functions and adequate electrolytes as per protocol~* Subject able to take oral medications~Exclusion Criteria:~* Prior systemic therapy for metastatic disease~* Prior treatment with any RAF inhibitor, MEK inhibitor, cetuximab or other anti-EGFR inhibitors~* Symptomatic brain metastasis or Leptomeningeal disease~* History or current evidence of Retinal Vein Occlusion (RVO) or current risk factors for RVO~* History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ≤ 12 months prior to first dose.~* Impaired cardiovascular function or clinically significant cardiovascular diseases: history of myocardial infarction or coronary disorders within 6 months prior to start of study treatment, symptomatic congestive heart failure (grade 2 or higher), past or current clinically significant arrhythmia and/or conduction disorder within 6 months prior to study treatment start~* History of thromboembolic or cerebrovascular events within 6 months prior to start of study treatment~* Concurrent neuromuscular disorder that is associated with potential elevation of Creatine Kinase~* Known contraindication to cetuximab administration as per SPC/approved label

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 Arm (Type: EXPERIMENTAL): encorafenib plus binimetinib plus cetuximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, ≥ 18 years of age~* HCV Genotype 1 or 4 who previously failed treatment with Peginterferon alfa-2a or peginterferon alfa-2b and Ribavirin (P/R), classified as previous null and partial responders based on previous therapy~* HCV RNA ≥ 10,000 IU/mL~* Seronegative for Human immunodeficiency virus (HIV) and Hepatitis B surface antigen (HBsAg)~* Subjects with compensated cirrhosis are permitted (compensated cirrhotics are capped at approximately 25% of treated population)~Exclusion Criteria:~* Prior treatment of HCV with HCV direct acting antiviral (DAA)~* Evidence of a medical condition contributing to chronic liver disease other than HCV~* Evidence of decompensated liver disease including, but not limited to, a history or presence of ascites, bleeding varices, or hepatic encephalopathy~* Diagnosed or suspected hepatocellular carcinoma or other malignancies~* Uncontrolled diabetes or hypertension~* Total bilirubin ≥ 34 μmol/L (or ≥ 2 mg/dL) unless subject has a documented history of Gilbert's disease~* Alanine aminotransferase (ALT) ≥ 5x Upper limit of normal (ULN)~* Albumin \< 3.5 g/dL (35 g/L)~* Alpha Fetoprotein (AFP) \> 100 ng/mL (\>82.6 IU/mL) or ≥ 50 and ≤ 100 ng/mL requires a liver ultrasound and subjects with findings suspicious of Hepatocellular carcinoma (HCC) are excluded~* Absolute neutrophil count (ANC) \< 1.5 x 1000,000,000 cells/L (\< 1.2 x 1000,000,000 cells/L for Black/African-Americans)~* Platelets \< 90 x 1000,000,000 cells/L~* Hemoglobin \< 12 g/dL for females or \< 13 g/dL for males~* Any criteria that would exclude the subject from receiving P/R

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QUAD: Asunaprevir+Daclatasvir+Peg-interferon Alfa-2a+Ribavirin (Type: EXPERIMENTAL): Asunaprevir: Capsule, Oral, 100 mg, Twice daily, 24 weeks~Daclatasvir: Tablet, Oral, 60 mg, Once daily, 24 weeks~Peg-interferon Alfa-2a: Injection, subcutaneous (SC), 180 mcg/0.5 mL, Once weekly, 24 weeks~Ribavirin: Tablet, Oral, 1000 mg/1200 mg (total daily dose), 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of mantle cell lymphoma ( MCL) must include morphology and expression of either cyclin D1 in association with one B-cell marker (for example, cluster of differentiation \[CD\] CD19, CD20, or paired box \[PAX5\]) or evidence of t(11;14) as assessed by cytogenetics, fluorescent in situ hybridization (FISH), or polymerase chain reaction (PCR)~* Received at least 1 prior lines of therapy for MCL (separate lines of therapy are defined as single or combination therapies that are either separated by disease progression or by a greater than 6-month treatment-free interval)~* At least 1 measurable site of disease according to the Revised Response Criteria for Malignant Lymphoma (that is, the site of disease must be greater than 1.5 centimeter \[cm\] in the long axis regardless of short axis measurement or greater than 1.0 cm in the short axis regardless of long axis measurement, and clearly measurable in 2 perpendicular dimensions)~* Have documented failure to achieve at least partial response (PR) with, or documented disease progression after, the most recent anti-MCL treatment regimen~* Eastern Cooperative Oncology Group performance status score of 0 or 1~Exclusion Criteria:~* Prior chemotherapy within 3 weeks, nitrosoureas within 6 weeks, therapeutic anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy within 3 weeks, or major surgery within 4 weeks of the first dose of study drug~* Prior treatment with ibrutinib or other Bruton's Tyrosine Kinase (BTK) inhibitors~* More than 5 prior lines of therapy for MCL (separate lines of therapy are defined as single or combination therapies that are either separated by disease progression or by a greater than 6-month treatment-free interval)~* Known central nervous system (CNS) lymphoma~* Woman who is pregnant, breast-feeding, or planning to become pregnant within 1 month after the last dose of study drug or is a man who plans to father a child while enrolled in this study or within 3 months after the last dose of study drug

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ibrutinib (Type: EXPERIMENTAL): Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a 28-day cycle up to 7 cycles or until disease progression (or relapse if the participant achieved a complete response \[CR\]), unacceptable toxicity, or end of treatment, whichever occurs first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Mineral Trioxide Aggregate in the Treatment of Traumatized Teeth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy patient~* Non-vital tooth with chronic periapical lesions~* Restorable tooth~* No horizontal or vertical root fractures~* No root resorption~Exclusion Criteria:~* Unrestorable tooth~* Horizontal or vertical root fractures~* Root resorption

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- ProRoot MTA (Type: EXPERIMENTAL): Traumatized permanent teeth obturated with ProRoot MTA after root canal treatment
- MTA+ Cercamed (Type: EXPERIMENTAL): Traumatized permanent teeth obturated with MTA+ Cerkamed after root canal treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline (SPARED) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women seeking care at the University of Rochester's Women's Health Practice Family Planning Clinic~* Undergoing second trimester surgical termination of pregnancy~* Proficient in reading, writing, and comprehending English~* Able to give informed consent~Exclusion Criteria:~* Not proficient in reading, writing, or comprehending English~* Not able to give informed consent~* Already taking antiemetics~* Doxycycline allergy~* Hyperemesis gravidarum~* History of gastroparesis or cyclical vomiting~* Unable to swallow pills

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 160 Patients will randomly be assigned, using sealed numbered opaque envelopes to receive placebo tablet 30 minutes prior to taking 200mg PO doxycycline
- Ondansetron (Type: ACTIVE_COMPARATOR): 160 Patients will randomly be assigned, using sealed numbered opaque envelopes to receive 8mg ondansetron tablet 30 minutes prior to taking 200mg PO doxycycline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete